Peter Noymer, PhD, the Company’s President and CEO, will be presenting at the Biotech Showcase 2019 at the Hilton San Francisco Union Square in San Francisco, CA.
| Date: Monday, January 7, 2019 |
| Time: 10:30 a.m. PDT |
| Location: Franciscan B (Ballroom Level) |
|
|
About Kedalion Therapeutics
Kedalion Therapeutics is a venture-backed, clinical-stage biotechnology company whose mission is to bring to market transformative topical ophthalmic therapies for new and existing indications. Kedalion’s proprietary AcuStream platform technology delivers topical drugs to the eye in a precise and accurate manner that enables comparable effect with up to an 80% reduction in dose compared to standard eye drops. Kedalion is based in Menlo Park, CA. For more information, visit www.kedalionthera.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190102005075/en/
Source: Kedalion Therapeutics, Inc.
View this news release online at:
http://www.businesswire.com/news/home/20190102005075/en
